Refine by
Surgical System For Abdominal Surgeries Articles & Analysis
10 news found
NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study Newsoara to fully fund Phase 3 program in China Under the Co-Development Agreement, commencement of Phase 3 program in China will trigger milestone payment to Palisade Bio Palisade Bio (Nasdaq: PALI), a clinical stage ...
- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET. Participating from the Palisade Bio management team will be Tom Hallam, Ph.D., Chief ...
” Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN) assessed the efficacy of LB1148 to reduce the formation of adhesions in subjects undergoing abdominal surgery. Study LBS-IST-POI-101 was a Phase 1, single-center, open-label, study enrolling 11 subjects undergoing GI surgery. ...
Adhesions can be found in up to 90% of cases after intra-abdominal surgery. Some patients will suffer life-long complications, and it’s also estimated that the US medical system spends more than $2 billion dollars a year on treating patients with postoperative adhesions,” said Michael Dawson, M.D., Chief Medical Officer, Palisade Bio. ...
MOUNTAIN VIEW, Calif., January 13, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Wireless Patch System (WPS) for non-invasive myoelectric activity measurement. The G-Tech WPS is a tool that provides gastric and intestinal myoelectrical ...
These procedures included general surgery, gynecology, urology, colorectal, pediatric, and bariatric surgical cases. ...
New Senhance Program Initiations The Company recently announced four new Senhance Robotic Surgery Program initiations. Three Japanese hospitals entered into agreements to lease a Senhance Surgical System, bringing the total number of Senhance programs in Japan to seven. The fourth program initiation was in Russia, following a hospital’s ...
Fibroids are treated from within the uterus, so treatment with the Sonata System requires no incisions, no tissue is surgically removed, and the uterus is retained. ...
EO2 Concepts announced today the release of a new, larger wound dressing for post-surgical dehiscence and large, painful leg ulcers. This new 5x7 OxySpur oxygen diffusion dressing is part of the OxyGeni System which provides a complete oxygen therapy and wound monitoring system. Continuous Diffusion of Oxygen (CDO) therapy provides full closure and pain relief to patients dealing with chronic, ...
Connecticut-based medical device innovator Lumendi, LLC has announced a change in the company’s Mission & Vision statements to better communicate the intended path of its innovative DiLumenTM Endolumenal Interventional Platform (EIP) to transform the GI landscape from surgical intervention to endolumenal. The new statement, Pioneering Endosurgery, will also be used as ...